Navigation Links
Promising Data Released on New Mesothelioma Therapy
Date:9/30/2015

At the 2015 World Conference on Lung Cancer, Dr. Raffit Hassan of the National Cancer Institute presented promising data on a novel agent, anetumab ravtansine, also known as BAY 94-9343. Anetumab ravtansine is an antibody-drug conjugate directed against the target molecule mesothelin which is highly expressed on mesotheliomas.

This was a phase I study to determine the safety and activity of anetumab ravtansine in patients with cancer who had failed standard therapies. Based on early results of this trial, more mesothelioma patients were enrolled to better define the activity of this drug in patients with pleural mesothelioma who had progressed on chemotherapy. Out of the 16 mesothelioma patients treated at the maximum tolerated dose, 5 (31%) had objective tumor shrinkage while 7 (44%) had stable disease. However, out of the 10 mesothelioma patients who received anetumab ravtansine as second line therapy, 5 (50%) had objective tumor shrinkage and 4 (40%) had stable disease. In most patients, the tumor response was very durable with three patients still receiving the drug more than two years after starting therapy.

“Anetumab ravtansine shows encouraging efficacy in patients with advanced mesothelioma which warrants further study,” stated Dr. Hassan, a senior investigator and the head of the Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute who has been working on developing mesothelin targeted therapies for patients with mesothelioma and other cancers for the last two decades.

Antibody-drug conjugates (also known as ADCs) are a new class of drugs that function by linking a particular antibody to a cancer-fighting drug. When combined, the antibody precisely targets the cancer cell, delivering the drug directly to it, thus avoiding extensive damage to healthy cells typical of traditional chemotherapies.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. With the life expectancy of less than one year after diagnosis, medical experts consider it one of the most aggressive and deadly of all cancers. An estimated one-third of those who develop mesothelioma were exposed while serving in the Navy or working in shipyards. Currently, few treatment options exist. There is no cure.

About The Mesothelioma Applied Research Foundation
The Meso Foundation is the only 501(c)(3) nonprofit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer-reviewed scientific research to develop life-saving treatments for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research. More information is available at http://www.curemeso.org.

###

Read the full story at http://www.prweb.com/releases/2015/10/prweb12991995.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study
2. WesternU and Sight Savers America provide vision-impaired children with a promising future
3. New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma
4. New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant
5. CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015
6. Neogenis® Labs Named to 2015 Austin A-List Most Promising Startups
7. Recent Research Points to Immunotherapy as Promising New Mesothelioma Approach, According to Surviving Mesothelioma
8. Cendyn/ONE™ named by CIO Review as one of the ‘20 Most Promising Travel & Hospitality Solution Providers’ for 2015
9. Invictus Medical Secures Rights to Second Promising New NICU Technology
10. CIO Review Selects storageFOUNDRY for the 20 Most Promising Storage Solution Providers 2015
11. Kavi Associates has been Awarded the 20 Most Promising SAS Solution Providers 2015 Award by CIO Review - Showcased as a Leader in Business Analytics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2019)... ... June 12, 2019 , ... Ovation Travel ... U.S., today announced that its Chairman and CEO Paul Metselaar has received the ... presented last Wednesday evening at New York City’s Capitale as part of the ...
(Date:6/12/2019)... , ... June 12, 2019 , ... ... significantly impacts their life, preventing them from participating in education or the workforce, ... will urge policymakers to recognize communication as a human right and address communication ...
(Date:6/11/2019)... (PRWEB) , ... June 11, 2019 , ... ... report on its recent workshop with government regulators, biopharma companies, and ... facioscapulohumeral muscular dystrophy (FSHD) . The Society is the world’s largest research-focused ...
(Date:6/6/2019)... CITY, Mo. (PRWEB) , ... June 05, 2019 ... ... accountable care, today announced the call for speaker proposals for its fourth annual ... in Scottsdale, Arizona. , The annual symposium brings together hundreds of health ...
(Date:6/6/2019)... ... ... The fourth annual event takes place on Saturday, June 8, at the Gulf Place Beach ... we feel it is important to be a positive influence in the community and connect ... along the Emerald Coast and we look forward to supporting this event each year,” said ...
Breaking Medicine News(10 mins):
(Date:6/13/2019)... ... June 13, 2019 , ... Recent lawsuits, including ... a back problem, underscore the responsibility of employers to provide reasonable accommodations to ... requests are reasonable and which are not - from requests by hearing-impaired and ...
(Date:6/13/2019)... Va. (PRWEB) , ... June 13, 2019 , ... The ... new executive director to succeed current executive director Nicholas Croce Jr., MS. The search ... of the Board of Directors, past APNA Presidents, and Council and Chapter leaders. , ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... years of educating medical professionals and the public about non-invasive photobiomodulation (PBM) therapy ... in Orlando, Florida to help commemorate the milestone. , Also known ...
Breaking Medicine Technology: